March Biosciences is a technology company.
March Biosciences has raised $28.0M across 1 funding round.
March Biosciences has raised $28.0M in total across 1 funding round.
March Biosciences is a clinical-stage biotechnology company developing CAR-T cell therapies for hematological cancers, particularly relapsed or refractory T-cell lymphomas.[1][2][4] Its lead product, MB-105, is a first-in-class CD5-targeted CAR-T therapy that selectively eliminates malignant CD5-positive cells while sparing healthy T-cells, addressing a patient population with poor prognosis (10-20% 3-year survival) and limited treatment options.[2][4] Founded in 2021 and headquartered in Houston, Texas, the company has raised $46.8M, recently securing a $200K grant, and serves patients with hematological malignancies through innovative cell therapies that prioritize cell quality, streamlined manufacturing, and new target spaces without complex gene editing.[1][2]
The company targets the $3B U.S. T-cell lymphoma market, showing strong growth momentum with Phase 1 trials yielding durable complete responses and a favorable safety profile, leading to a multi-center Phase 2 trial initiated in April 2025 that has begun dosing patients.[4][6]
March Biosciences was founded in 2021 in Houston, Texas, by Sarah Hein, PhD, who serves as CEO and co-founder, alongside a team of leading cell therapy scientists and drug developers.[1][2][5] The idea emerged from recognizing unmet needs in hematological cancers, particularly T-cell lymphomas where on-target, off-tumor toxicity has limited targeted therapies.[2][4] Early traction came from developing MB-105's proprietary CAR construct, which demonstrated promising Phase 1 results including long-term complete responses, prompting FDA Orphan Drug Designation in January 2025 and the Phase 2 trial launch shortly after.[4]
Pivotal moments include recent grants like the G-Rex® award for manufacturing advancement and dosing the first Phase 2 patient in 2025, building on the founders' expertise in cell therapy innovation.[1][4]
March Biosciences rides the CAR-T expansion wave beyond solid tumors into hematological niches like T-cell lymphoma, where narrow therapeutic options and high unmet need create opportunity amid a $3B annual U.S. market.[4][6] Timing aligns with maturing cell therapy infrastructure—improved manufacturing and regulatory nods like Orphan Drug status—fueled by market forces such as rising cancer incidence and investor interest in precision oncology.[1][4] The company influences the ecosystem by pioneering CD5 targeting, potentially expanding CAR-T applicability, de-risking similar therapies, and contributing to Houston's biotech hub growth.[1][2]
March Biosciences is poised for Phase 2 readouts from its 46-patient trial, with enrollment across U.S. sites potentially yielding registrational data by 2026-2027 if efficacy holds.[4] Trends like refined manufacturing and combination regimens will shape its path, amplifying impact in underserved lymphomas. Its influence may evolve through partnerships or Series B funding, solidifying CAR-T as a cornerstone for hematological cancers—transforming dire prognoses into curable outcomes, much like its mission to unlock new target spaces.[2]
March Biosciences has raised $28.0M in total across 1 funding round.
March Biosciences's investors include 4BIO Capital, Business Growth Fund.
March Biosciences has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $28.0M Series A | 4BIO Capital, Business Growth Fund |